A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Status:
RECRUITING
Trial end date:
2028-07-31
Target enrollment:
Participant gender:
Summary
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.